Chimpanzee adenoviral vectors as vaccines–challenges to move the technology into the fast lane

Expert Review of Vaccines

Volumn 16, Issue 12, 2017, Pages 1241-1252

  Vitelli, Alessandra ^a   Folgori, Antonella ^a   Scarselli, Elisa ^b   Colloca, Stefano ^a   Capone, Stefania ^a   Nicosia, Alfredo ^a,c,d  

^a ReiThera ^*  (Italy)

^b Nouscom srl   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

chimpanzee adenovirus; immunity; mucosal immunity; T cells; Vaccine; viral vector

Indexed keywords

ADENOVIRUS VECTOR; VACCINE; DRUG CARRIER;

CHIMPANZEE; DRUG EFFICACY; DRUG POTENCY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MUCOSAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTYPE; VIRUS CHARACTERIZATION; VIRUS ISOLATION; ADENOVIRIDAE; ANIMAL; CLINICAL TRIAL (TOPIC); GENE VECTOR; GENETICS; IMMUNOLOGY; PAN TROGLODYTES; PHARMACEUTICS; PRECLINICAL STUDY; PROCEDURES;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; GENETIC VECTORS; HUMANS; PAN TROGLODYTES; TECHNOLOGY, PHARMACEUTICAL; VACCINES;

EID: 85034115669     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2017.1394842     Document Type: Review

References (111)

1. Vaidya SA, Cheng G., Toll-like receptors and innate antiviral responses. Curr Opin Immunol. 2003;15(4):402–407.
2. Lupfer C, Malik A, Kanneganti TD., Inflammasome control of viral infection. Curr Opin Virol. 2015;12:38–46.
3. Dalod M, Chelby R, Malissen B, et al. Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming. Embo J. 2014;33(10):1104–1116.
4. Ertl HC. Viral vectors as vaccine carriers. Curr Opin Virol. 2016;21:1–8.
5. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther. 2004;10(4):616–629.
6. Ebner K, Pinsker W, Lion T. Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications. J Virol. 2005;79(20):12635–12642.
7. Alonso-Padilla J, Papp T, Kajàn GL, et al. Development of novel adenoviral vectors to overcome challenges observed with HAdV-5-based constructs. Mol Ther. 2016;24(1):6–16.
8. Roelvink PW, Lizonova A, Lee JGM, et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol. 1998;72(10):7909–7915.
9. Mathias P, Wickham T, Moore M, et al. Multiple adenovirus serotypes use alpha v integrins for infection. J Virol. 1994;68(10):6811–6814.
10. Sirena D, Lilienfeld B, Eisenhut M, et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol. 2004;78(9):4454–4462.
11. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med. 2004;6(Suppl 1):S164–71.
12. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood. 2007;110(6):1916–1923.
13. Reyes-Sandoval A, Fitzgerald JC, Grant R, et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol. 2004;78(14):7392–7399.
14. Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012;4(115):115ra2.
15. Xiang Z, Li Y, Cun A, et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis. 2006;12(10):1596–1599.
16. Ludwig SL, Brundage JF, Kelley PW, et al. Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. J Infect Dis. 1998;178(6):1776–1778.
17. Thorner AR, Vogels R, Kaspers J, et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol. 2006;44(10):3781–3783.
18. Chen H, Xiang ZQ, Li Y, et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol. 2010;84(20):10522–10532.
19. Zak DE, Andersen-Nissen E, Peterson ER, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci U S A. 2012;109(50):E3503–12.
20. Cichon G, Boeckh-Herwig S, Schmidt HH, et al. Complement activation by recombinant adenoviruses. Gene Ther. 2001;8(23):1794–1800.
21. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–1893.
22. Wigand R. Pitfalls in the identification of adenoviruses. J Virol Methods. 1987;16(3):161–169.
23. Phan TG, Vo NP, Boros A, et al. The viruses of wild pigeon droppings. PLoS One. 2013;8(9):e72787.
24. Roy S, Vandenberghe LH, Kryazhimskiy S, et al. Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. PLoS Pathog. 2009;5(7):e1000503.
25. Abbink P, Maxfield LF, N’ga’nga D, et al. Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors. J Virol. 2015;89(3):1512–1522.
26. Johnson TR, Rangel D, Graham BS, et al. Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol Ther. 2014;22(1):196–205.
27. Roy S, Medina-Jaszek A, Wilson MJ, et al. Creation of a panel of vectors based on ape adenovirus isolates. J Gene Med. 2011;13(1):17–25.
28. Tatsis N, Tesema L, Robinson EL, et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 2006;13(5):421–429.
29. Burgert HG, Blusch JH. Immunomodulatory functions encoded by the E3 transcription unit of adenoviruses. Virus Genes. 2000;21(1–2):13–25.
30. Dobner T, Horikoshi N, Rubenwolf S, et al. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science. 1996;272(5267):1470–1473.
31. Dicks MD, Spencer AJ, Edwards NJ, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One. 2012;7(7):e40385.
32. Machitani M, Sakyrai F, Wakabayashi K, et al. Enhanced oncolytic activities of the telomerase-specific replication-competent adenovirus expressing short-hairpin RNA against dicer. Mol Cancer Ther. 2017;16(1):251–259.
33. Farina SF, Gao G, Xiang ZQ, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol. 2001;75(23):11603–11613.
34. Roy S, Gao G, Lu Y, et al. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum Gene Ther. 2004;15(5):519–530.
35. Jian L, Zhao Q, Zhang S, et al. The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China. Arch Virol. 2014;159(3):465–470.
36. Zhang S, Huang W, Zhou X, et al. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J Med Virol. 2013;85(6):1077–1084.
37. Green CA, Scarselli E, Sande CJ, et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med. 2015;7(300):300ra126.
38. Hutnick NA, Carnathan D, Demers K, et al. Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine. 2010;28(8):1932–1941.
39. Calcedo R, Vandenberghe LH, Roy S, et al. Host immune responses to chronic adenovirus infections in human and nonhuman primates. J Virol. 2009;83(6):2623–2631.
40. Kobinger GP, Feldman HY, Zhi, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006;346(2):394–401.
41. Xiang ZQ, Greenberg L, Ertl HC, et al. Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology. 2014;450–451:243–249.
42. Quinn KM, Da Costa A, Yamamoto A, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol. 2013;190(6):2720–2735.
43. Arnberg N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol. 2009;19(3):165–178.
44. Tatsis N, Bleyer A, Lasaro MO, et al. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther. 2007;15(3):608–617.
45. Adams WC, Gujer C, McInerney G, et al. Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation. Proc Natl Acad Sci U S A. 2011;108(18):7499–7504.
46. Hensley SE, Cun AS, Giles-Davis W, et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol Ther. 2007;15(2):393–403.
47. Kahl CA, Bonnell J, Hiriyanna S, et al. Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine. 2010;28(35):5691–5702.
48. Teigler JE, Iampietro MJ, Barouch DH. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J Virol. 2012;86(18):9590–9598.
49. Quinn KM, Zak DE, Costa A, et al. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. J Clin Invest. 2015;125(3):1129–1146.
50. Reyes-Sandoval A, Shridar S, Bertohud T, et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol. 2008;38(3):732–741.
51. Reyes-Sandoval A, Berthoud T, Alder N, et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun. 2010;78(1):145–153.
52. Cheng T, Wang X, Song Y, et al. Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1. Vaccine. 2016;34(41):4875–4883.
53. Vitelli A, Quirion MR, Lo C, et al. Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus. PLoS One. 2013;8(3):e55435.
54. Zhou D, Cun A, Li Y, et al. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther. 2006;14(5):662–672.
55. Taylor G, Thom M, Capone S, et al. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. Sci Transl Med. 2015;7(300):300ra127.
56. Stylianou E, Griffiths KL, Poyntz HC, et al. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. Vaccine. 2015;33(48):6800–6808.
57. Fitzgerald JC, Gao GP, Reyes-Sandoval A, et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol. 2003;170(3):1416–1422.
58. Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20(10):1126–1129.
59. Warimwe, GM, Lorenzo G, Lopez-Gil E, et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol J. 2013;10:349.
60. Warimwe GM, Lorenzo G, Lopez-Gil E, et al. Chimpanzee adenovirus vaccine provides multispecies protection against rift valley fever. Sci Rep. 2016;6:20617.
61. Krause A, Whu WZ, Zu Y, et al. Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF. Vaccine. 2011;29(11):2131–2139.
62. Ewer KJ, O’Hara GA, Duncan CJ, et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013;4:2836.
63. Dicks MD, Guzman E, Spencer AJ, et al. The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. Vaccine. 2015;33(9):1121–1128.
64. Mestecky J, Russell MW, Elson CO. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J Immunol. 2007;179(9):5633–5638.
65. Iwasaki A. Exploiting mucosal immunity for antiviral vaccines. Annu Rev Immunol. 2016;34:575–608.
66. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(4 Suppl):S45–53.
67. Kaufman DR, Bivas-Benitas M, Simmons NL, et al. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J Virol. 2010;84(12):5986–5996.
68. Bolton DL, Song K, Tomaras GD, et al. Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques. Vaccine. 2017;35(4):639–646.
69. Lai R, Afkhami S, Haddadi S, et al. Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments. Eur Respir Rev. 2015;24(136):356–360.
70. Jeyanathan M, Thanthrige-Don N, Afkhami S, et al. Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection. Mucosal Immunol. 2015;8(6):1373–1387.
71. Varnavski AN, Schlienger K, Bergelson JM, et al. Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector. Hum Gene Ther. 2003;14(6):533–544.
72. Zens KD, Farber DL. Memory CD4 T cells in influenza. Curr Top Microbiol Immunol. 2015;386:399–421.
73. Price GE, Lo C, Misplon JA, et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One. 2010;5(10):e13162.
74. Van Kampen KR, Shi Z, Gao P, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2005;23(8):1029–1036.
75. Weaver EA, Nehete PN, Nehete BP, et al. Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. PLoS One. 2013;8(7):e67574.
76. Dudareva M, Andrews L, Gilbert SC, et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine. 2009;27(27):3501–3504.
77. O’Hara GA, Duncan CJ, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis. 2012;205(5):772–781.
78. Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012;7(2):e31208.
79. Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther. 2011;19(12):2269–2276.
80. De Barra E, Hodgson SH, Ewer KJ, et al. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS One. 2014;9(12):e115161.
81. Hodgson SH, Ewer KJ, Bliss CM, et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis. 2015;211(7):1076–1086.
82. Sheehy SH, Duncan CJ, Elias SC, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2012;20(12):2355–2368.
83. Hodgson SH, Choudhary P, Elias SC, et al. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial. Mol Ther. 2014;22(12):2142–2154.
84. Borthwick N, Ahmed T, Ondondo B, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther. 2014;22(2):464–475.
85. Hayton EJ, Rose A, Ibrahimsa U, et al. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One. 2014;9(7):e101591.
86. Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med. 2014;6(261):261ra153.
87. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4(115):115ra1.
88. Ewer K, Rampling T, Venkatraman N, et al. A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA. N Engl J Med. 2016;374(17):1635–1646.
89. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector ebola vaccine. N Engl J Med. 2017;376(10):928–938.
90. Tapia MD, So SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16(1):31–42.
91. De Santis O, Audran R, Potin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16(3):311–320.
92. Antrobus RD, Coughlan L, Berthoud TK, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther. 2014;22(3):668–674.
93. Moorthy VS, McConkey S, Roberts M, et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine. 2003;21(17–18):1995–2002.
94. Ogwang C, Kimani D, Edwards NJ, et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med. 2015;7(286):286re5.
95. Bliss CM, Drammeh A, Bowyer G, et al. Viral vector malaria vaccines induce high-level T cell and antibody responses in West African children and infants. Mol Ther. 2017;25(2):547–559.
96. Akondy RS, Monson ND, Miller JD, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183(12):7919–7930.
97. Henao-Restrepo AM, Camacho A, Longini IN, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–866.
98. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med. 2016;374(17):1647–1660.
99. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10(1):116–125.
100. Bolinger B, Sims S, Swadling L, et al. Adenoviral vector vaccination induces a conserved program of CD8(+) T cell memory differentiation in mouse and man. Cell Rep. 2015;13(8):1578–1588.
101. Hutnick NA, Carnathan DG, Dubey SA, et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med. 2009;15(8):876–878.
102. O’Brien KL, Liu Y, King SL, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med. 2009;15(8):873–875.
103. Hutnick NA, Carnathan DG, Dubey SA, et al. Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality. PLoS One. 2010;5(12):e14385.
104. Leen AM, Christin A, Khalil M, et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008;82(1):546–554.
105. Frahm N, DeCamp AC, Friedrick DP, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest. 2012;122(1):359–367.
106. Spencer AJ, Cottingham MG, Jenks JA, et al. Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain. PLoS One. 2014;9(6):e100538.
107. Capone S, Naddeo M, D’Alise AM, et al. Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates. Mol Ther. 2014;22(5):1039–1047.
108. Knowles MK, Nadin-Davis SA, Sheen M, et al. Safety studies on an adenovirus recombinant vaccine for rabies (AdRG1.3-ONRAB) in target and non-target species. Vaccine. 2009;27(47):6619–6626.
109. Pearson FE, McNeilly CL, Crichton ML, et al. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS One. 2013;8(7):e67888.
110. Ghobadloo SM, Balcerzak AK, Gargaun A, et al. Carbohydrate-based ice recrystallization inhibitors increase infectivity and thermostability of viral vectors. Sci Rep. 2014;4:5903.
111. Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, et al. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol. 2014;27:89–97.